BUZZ - Omeros shares fall as third-quarter revenue misses expectations
路透社2026/11/17 13:36November 17 - ** Pharmaceutical company Omeros (OMER.O) saw its share price fall 8.1% in pre-market trading to $15.33
** If the decline continues, the opening price will hit a three-month low
** According to data compiled by London Stock Exchange Group (LSEG), the Seattle, Washington-based company's third-quarter revenue was $36 million, below analysts' expectations of $37.3 million
** However, adjusted earnings per share for the third quarter were 6 cents, higher than the market expectation of 3 cents
** Growth in sales of OMER's stem cell transplant-related vascular injury drug Yartemlea was partially offset by an increase in participation in the 340B program
** The 340B program requires pharmaceutical companies to sell drugs to designated hospitals and clinics at discounted prices
** At the end of the last trading day, the stock was down 2.9% year to date
(To facilitate non-English speakers, Reuters has automated the translation of its reporting into several other languages. As automated translation may contain errors or lack the desired context, Reuters does not guarantee the accuracy of the automated translation text, and it is provided solely for reader convenience. Reuters does not accept any liability for any damage or loss caused by the use of the automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Moody's: Downgrades NVIDIA outlook

Chris Vermeulen warns of deeper market selloff, sees gold falling to $3,100
Why the Unexpectedly Strong Earnings Report Couldn't Save Nvidia
Report: The European Central Bank plans to discuss raising the minimum reserve requirement from 1% to 2%
According to media reports, the European Central Bank’s Governing Council plans to discuss raising the minimum reserve requirement from the current 1% to 2% at its meeting on November 25. This move could save at least 4.4 billion euros annually for the ECB and 21 national central banks in the euro area, while also absorbing some of the excess liquidity in the system.